Bispecific antibodies, a novel immunotherapy for multiple myeloma, create immune synapses between T-cell marker CD3 and malignant cell markers like B-cell maturation antigen (BCMA), FcRH5, and GPRC5D, effectively depleting plasma cells and some T-cells, which increases infection risk.
